Volume 5 Supplement 1

2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications

Open Access

NO/cGMP signalling

  • Doris Koesling1Email author,
  • Evanthia Mergia1,
  • Michael Russwurm1,
  • Florian Mullershausen1,
  • Corina Wagner1,
  • Alexander Lange1 and
  • Andreas Friebe1
BMC Pharmacology20055(Suppl 1):S10

https://doi.org/10.1186/1471-2210-5-S1-S10

Published: 16 June 2005

Most of the effects of the signalling molecule nitric oxide (NO) are mediated by the stimulation of the NO-sensitive guanylyl cyclase (GC) and the subsequent increase in cGMP formation. The enzyme contains a prosthetic heme group which mediates NO stimulation. In addition to the physiological activator NO, NO-sensitisers like the substance YC-1 sensitise the enzyme towards NO and may therefore have important pharmacological implications. Two isoforms of NO-sensitive GC have been identified to date that share regulatory properties but differ in the subcellular localization; the more ubiquitously expressed α1β1 heterodimer and the α2β1 isoform mainly expressed in brain. Knock-out mice in which either one the GC subunits is deleted will provide information about the functional roles of GC and the isoforms.

In intact cells, NO-induced cGMP signalling not only depends on cGMP formation but is also critically determined by the activity of the enzyme responsible for cGMP degradation i.e. phosphodiesterase 5 (PDE5). Recently, direct activation of PDE5 by cGMP was demonstrated which is limiting the cGMP increase and therefore is functioning as a negative feedback. As the cGMP-induced PDE5 activation turned out to be sustained, in the range of hours, it is probably responsible for the NO-induced desensitisation observed within NO/cGMP signalling.

Authors’ Affiliations

(1)
Institut für Pharmakologie, Ruhr-Universität Bochum

Copyright

© BioMed Central Ltd 2005

Advertisement